Posted by Michael Wonder on 27 Oct 2023
Altimmune granted fast track designation by FDA for pemvidutide for the treatment of non-alcoholic steatohepatitis
26 October 2023 - Altimmune today announced that the US FDA has granted fast track designation to its clinical program investigating pemvidutide for the treatment of non-alcoholic steatohepatitis.
The efficacy and safety of pemvidutide in non-alcoholic steatohepatitis are being evaluated in IMPACT, a Phase 2b randomised, placebo-controlled biopsy-driven trial that is being conducted at approximately 60 sites in the US.
